Glasgow Biomedicine

What is Glasgow Biomedicine?

Established in 2003, Glasgow Biomedicine is a joint initiative between the University of Glasgow and NHS Greater Glasgow & Clyde (NHS GG&C). Glasgow Biomedicine brings together the University and six Glasgow hospital sites creating an integrated, interdisciplinary centre of excellence for the management and execution of both non-commercial and commercial clinical trials research.

Our location, coupled with well-established operational, management and governance systems ensures that Glasgow Biomedicine offers solutions in clinical research that are:

• coordinated

• timely

• interdisciplinary

• cost-effective

The nature of clinical trials is likely to change as a result of the translational paradigm for drug development, as well as more personalised approaches to treatment in medical practice which depend on the genetic makeup of each patient. Glasgow’s bidirectional translational infrastructure, bridging scientific, clinical and other disciplines, places us in an extremely strong position to respond to any future needs and changes in clinical trials.

Great breadth of expertise, coupled with well-established clinical and research governance systems, and sound operational and management frameworks ensures Glasgow Biomedicine offers coordinated, interdisciplinary, timely and cost-effective solutions in clinical trials research.

Through the Glasgow Clinical Trials Unit, Glasgow Biomedicine facilitates and supports the initiation of over 600 new trials per annum and typically manages the on-going operation of around 1500 trials in a given year, with an average spend of £15.5M per annum executing such clinical research.

How do we achieve this?

Key Location
Glasgow’s context in Scotland carries the advantage of access to a large patient base with high levels of morbidity:

• 41% of Scotland’s population (2.3M) live within Glasgow Biomedicine’s catchment;
• a large majority of all commercial studies conducted in Scotland involve Glasgow Biomedicine.

Study management experience and a key location means Glasgow Biomedicine represents an attractive place to do business.

Advanced Data Management
The ability to access high quality data complements our expertise.  The Community Health Index (CHI), a unique patient-related number used in Scotland for all health communications, enables us to link data and facilitate detailed patient-based analysis and follow-up. This affords a comprehensive view of the totality of patient care information and morbidity data.